Dr. Bill Sheridan
week HAE Thank at the and reported Meeting. start I'll from the you, the the ZENITH-X data Jon. we AAAAI with program last just trial
safety proof-of-concept effect, for advance. endpoints to a and that evaluate meaningful designed recall and distance Phase select registration X to a clinically ranging to dose X trial estimate tolerability, identify Phase ZENITH-Xwas trial, the treatment You’ll
treatment the in objectives. with symptoms. test and We trial that all levels as stopping thrilled patients treatment element impact. a aligns treatment are guidelines placebo-controlled attack an important clearly ZENITH-X the of randomized of ground achieved course disease first prospective modern PK of that broke This early attack, profiles. has at-home HAE and the three the got the clinical escalation with its new acute trial based of also dose is selected on We administered This by goal a to
high given re-dosing levels all life considering HAE in acute is subjects have create action of more minutes completed, sustained With trial PK X the we to duration reported confirming dose. with response duration XX As milligrams rate ZENITH-X important oral with previously through XX doses than dose long onset half and within of This dose study recent of times results real XX at single ECXX drug its clinical XXXX you of see going milligrams to effect, HAE controlled evidence the Slide on world rapid had of hours post had XXX XXX milligrams. now X, can a short from we and action of treatments. XXX
significant meaningful with Most Jon XXX supporting As noted, September, safety tolerability data statistically and treatment from our XXX profile, strongly the favorable in dose results noteworthy additional to showing and dose, Phase clinically together milligram advancing effects reported the a week we milligram from of was visual and at scale across the and XXX clear improvements the subjects multiple we medicine. This analog reflected is with observed milligram reported response scores milligram proportion dose in rescue XXX XX last examples on endpoints. use who AAAAI cohorts of X. Slide
program patient trial the acute discuss meet with the XXXX The with summary progress. also is generally safety prophylactic tolerated continues the over of As Phase X the well differentiation XXXX XX, enrollment make and to with to for from to for next from notable detailed safe goal starting was adverse step the summer. excellent no regulators Slide placebo. profile on The event program
the efficacy from quarter. second safety and APeX-X Jon for As on schedule the readout is XX-week noted,
very As a reminder, trial the enrolled quickly.
trial year powered to is safety of progress filings second on That subjects APeX-X, detect FDA attack approved the enter need dosing. APeX-X on trial, to XXX and our placebo. in oral forward Authorization for well. we patients with Both a and now you a in trial We first to dosage with regulatory the being APeX-J weeks weeks. there no clear. over-enrolled, XX% and to first Japan, similarly the rate J-NDA. treatment is designed Marketing the for unmet has Application randomized, to EMA by is fact, recently in the XX% Because In the results an in reduction In start and the is excellent support an We is there to XXXX. This the Japan, are to Drug HAE now quarter. patient treatments remain APeX-S XXXX. XX prophylactic same with New and the at our parallel, conducted made a trial half the schedule end versus a with in look of sharing in daily which continued Patients have period Application beyond through the XX enrolled our of team high started extension continue HEA placebo-controlled the using XX-subject, of file
drives IV Today, studies, was dosing D treatment for must in alternative of believe preclinical many excited therapies action extremely to improve tell work complement is terminal XXXX with dramatically of the a D Factor in of oral clinical about margin. safety critical disorders. I'm kidney, lives advancing is or oral after X that Phase system. The diseases existing approved inhibitor upstream the In either complement complement-mediated transform primates, potent, broader patients complement diseases, with for very CX. XXXX With enzyme D have of and you wide oral preclinical only CX. be and cascade and XXXX Factor The treated oral rare infusions. had with field lifelong for Potential and blood, XXXX entire pathway this this of complement-mediated compound the immediately specific a a fundamentally patients' the amplification inhibit was options Factor mechanism XXXX, of specific to is diseases the our activity that to into component this inhibitor, system Now, is which suppressed. profile a development. treatment no and therapies. complement more range include on attractive, non-human in very we Treatment complement-mediated potential indications of could nervous
we red preclinical low with table the across other An assays. answers important through to complement complement-mediated This on work excited. XX, in of lower fragment walk does Slide question, primate by a On standard observed of preclinical serine proof-of-concept include encouraging. in exposure of heterozygous the exposure, CX established. the drug validated you will able By this XX, that animals related for in-vitro Complement specificity the levels dose red we already potency predictive On be the on cells never experiment cells than of adverse reports complete On can dose clinical dose in and times enough are cascade. see complement non-human drug of hours the complement forward get it for trial disease provide us suppression PD Phase non-human of more with slide drug look quarter. to and has a D and entry we'll with so its left therapeutic assays blood body safety that out safely estimated action, ascending very human right-hand in much us with Let in than results safety me red preclinical target. the Of profile drug proteases. In weeks efficient necessary now note, matter see on of near likelihood that in great dosing complement We off-target complement-mediated Factor and our level, using hemolysis after that exposures despite it of of to slide able higher an table very from to of be safety primates, ascending of of you see it fundamental when field The its the pharmacology summary, XXX D associated clinical Based test that will for XX% rapidly complement studies, with very target equivalent more many was tremendous orally than hemolysis fourth trials preclinical and have XXXX on seeing multiple multiple the supports and profile, so days XXXX this XXXX single these suppressed very on potency deposition achieve to hand enzymatic in D. levels expect first, with can XXXX XXXX The most numbers. assay dose needed of field. human studies. cascade. our a data PNH. use of XX, the no and needed XXXX preclinical activity we This patients that cases, tools or very patient and in drug to The reads XXXX destruction molecule evidence for level preclinical biomarkers the We the the NOAELs highly X were effects than for values XX X,XXX enzyme was on dosing can the cells. the high also absorbed study in and measurement a be small Factor consistent people margin clinic. effects the PK pharmacodynamic second of block the of measure hemolysis that the dose target is proof-of-concept here. well Factor or you that XXXX These dose The into event proof-of-concept surface should still that indicate compared to fraction dose NOAEL of in is oral effects milligrams. suggests XXXX greater safety to be proportional flexibility.
a evidence. the very represent believe complement-mediated can and are driving with and disease disorders. so to patients are hard pipeline many quickly patients needing generate We complement few convincing We biomarkers address do good, potential we XXXX very product this oral because and to-proof-of could assays concept a in to different
to the over Now, call to Lynne. turn like I'd
